N. N. Petrov National Medical Research Center of Oncology, Ministry of Health of the Russian Federation, St. Petersburg, Russia.
Bull Exp Biol Med. 2024 May;177(1):39-43. doi: 10.1007/s10517-024-06127-7. Epub 2024 Jul 2.
Female C57BL/J mice with pulmonary fibrosis induced by injections of bleomycin (20 mg/kg intraperitoneally, 8 times for 4 weeks) were treated with a lignin derivative-based composition BP-C3 (80 mg/kg, daily intragastric administrations for 4 weeks). Bleomycin treatment increased the severity of pulmonary fibrosis (Ashcroft score increased from 1.43±0.20 to 4.17±0.48) and the percentage of α-SMA tissue (from 15.22±1.01 to 33.12±2.30%) and DNA-synthetizing nuclei (from 1.05±0.14 to 3.38±0.375). After treatment with BP-C3, we observed a tendency to a decrease in Ashcroft score (to 3.40±0.51) and a significant decrease in the percentage of α-SMA tissue to 24.30±1.70%; the percentage of DNA-synthetizing nuclei decreased to a lesser extent (to 3.03±0.22%). These results suggest that BP-C3 has a moderate antifibrotic activity.
雌性 C57BL/J 小鼠经博来霉素(20mg/kg 腹腔注射,8 次,共 4 周)诱导肺纤维化后,用木质素衍生物 BP-C3 (80mg/kg,每日灌胃给药,共 4 周)进行治疗。博来霉素治疗增加了肺纤维化的严重程度(阿什克罗夫特评分从 1.43±0.20 增加到 4.17±0.48)和α-SMA 组织的百分比(从 15.22±1.01 增加到 33.12±2.30%)和 DNA 合成核的百分比(从 1.05±0.14 增加到 3.38±0.375)。用 BP-C3 治疗后,我们观察到阿什克罗夫特评分有下降的趋势(降至 3.40±0.51),α-SMA 组织的百分比显著下降至 24.30±1.70%;DNA 合成核的百分比下降幅度较小(降至 3.03±0.22%)。这些结果表明,BP-C3 具有中等的抗纤维化活性。